Galderma R&d
Clinical trials sponsored by Galderma R&d, explained in plain language.
-
New drug aims to harden less: nemolizumab trial for scleroderma
Disease control Recruiting nowThis phase 2 trial tests nemolizumab, an injectable drug, in 162 adults with systemic sclerosis (a disease causing skin hardening and organ damage). The main goal is to see if it reduces skin thickness over 52 weeks compared to a placebo. Researchers will also check lung function…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New eczema drug tested in everyday clinics on 1,000 patients
Disease control Recruiting nowThis study is tracking 1,000 teens and adults with moderate-to-severe atopic dermatitis (eczema) who are starting nemolizumab as part of their normal medical care. Researchers will measure how much the skin clears up and how much itching improves after 6 months. The goal is to se…
Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Sculptra shots aim to smooth cheek wrinkles in new study
Symptom relief Recruiting nowThis study tests Sculptra injections to improve cheek wrinkles and skin looseness in 25 women aged 45-65. Participants receive up to three treatments, and researchers use special cameras to measure skin changes over time. The goal is to see if this cosmetic procedure works and ho…
Phase: NA • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 24, 2026 04:52 UTC
-
New drug targets mysterious chronic itch
Symptom relief Recruiting nowThis Phase 2 study tests a drug called nemolizumab in 50 adults with chronic itching that has no known cause. The goal is to see how the drug works in the body and whether it can reduce itching over 16 weeks. Participants receive either nemolizumab or a placebo injection.
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 22, 2026 11:55 UTC
-
New acne cream shows promise in chinese trial
Symptom relief Recruiting nowThis study tests a cream called trifarotene on Chinese people aged 9 and older with moderate acne on the face and upper body. About 561 participants will apply the cream or a placebo daily for 12 weeks. The goal is to see if the cream reduces acne lesions and improves skin appear…
Phase: PHASE3 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 09, 2026 12:07 UTC
-
New Real-World study tests nemolizumab for chronic itch condition
Symptom relief Recruiting nowThis study looks at how well the drug nemolizumab works for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. Researchers will track 600 participants over 6 months in real-world clinics, measuring itch severity and skin lesi…
Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 09, 2026 12:07 UTC
-
Can a filler boost your Skin's look? new study tests restylane
Symptom relief Recruiting nowThis study tests if Restylane Skinboosters Vital Lidocaine can improve facial skin quality, like reducing fine lines. About 171 Chinese adults will either get the treatment or no treatment. The goal is to see if the treatment makes a visible difference in skin smoothness.
Phase: NA • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 08, 2026 13:18 UTC
-
Menopausal Women's skin changes under microscope in new study
Knowledge-focused Recruiting nowThis study looks at how a treatment called poly L-lactic acid (PLLA) changes proteins in the skin of menopausal women with cheek wrinkles. About 40 women will receive the treatment, and small skin samples will be taken to measure these changes. The goal is to understand how the t…
Phase: NA • Sponsor: Galderma R&D • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:48 UTC